samedan logo
 
 
 
spacer
home > ebr > spring 2003 > spr analysis of rationally designed anti-her2 exocyclic mimetics of antibodies
PUBLICATIONS
European Biopharmaceutical Review

SPR Analysis of Rationally Designed Anti-HER2 Exocyclic Mimetics of Antibodies

A series of peptide mimetics, based on the structure of the CDR3 loop of the anti-HER2 mAb 4D5, an anti-oncoprotein therapeutic monoclonal antibody, have been designed. The peptides can disable the tyrosine kinase, p185HER2/neu (HER2), an oncoprotein commonly expressed in human breast, ovarian and colon cancers. In SPR studies, the peptides have been shown to directly bind to HER2 and to compete with mAb 4D5 for receptor binding. Dissociation rate constants were shown to be important determinants of anti-tumorigenic activity of the peptides.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By Dr Ramachandran Murali, Assistant Professor in the Department of Pathology and Laboratory of Medicine at the University of Pennsylvania, USA

Dr Ramachandran Murali

Dr Ramachandran Murali is Assistant Professor in the Department of Pathology and Laboratory of Medicine, University of Pennsylvania School of Medicine. He is also a visiting academic at the Sir William Dunn School of Pathology, Oxford University, UK and a well trained and established structural biologist. He obtained his doctoral degree in Biophysics from the University of Madras, India, one of the pioneering institutes for structural biology in India.

Since then Dr Murali has expanded his expertise in macromolecular crystallography, immunology and cancer biology. His laboratory is mainly interested in the structure and function aspects of cell surface receptors relevant for cancer biology and immunology. His contributions include antibody structures, small molecule modifiers of receptors which have therapeutic applications in cancer biology, and autoimmune pathologies. He has developed several therapeutically relevant small molecules in the Department of Pathology and Laboratory Medicine, Center for Receptor Biology and Cell Growth at the University of Pennsylvania School of Medicine.


spacer
Dr Ramachandran Murali
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Engineered llama antibodies neutralise Covid-19 virus

Researchers have developed a family of engineered nanobodies which neutralise the SARS-CoV-2 virus, targeting the viral spike protein in a novel way.
More info >>

White Papers

Finding the Right End-to-End Safety Solution for Your Needs

Bioclinica

With upcoming changes, including the implementation of the International Conference on Harmonisation (ICH) E2B(R3) Electronic Transmission of Individual Case Safety Report and Identification of Medicinal Products (IDMP) standards, the current state of safety reporting can be confusing. Your existing safety system may not be flexible enough to accommodate these changing regulations, which are still moving targets regarding the details needed for a comprehensive solution with the right level of processes, company-to-company integrations and finalized regional rules.
More info >>

 
Industry Events

World Vaccine Congress Washington

27-29 September 2020, Walter E Washington Convention Center, Washington, US

The World Vaccine Congress is an award-winning series of conferences and exhibitions that have grown to become the largest and most established vaccine meeting of its kind across the globe. Our credibility is show through the prestigious scientific advisory board that spend months of hard work creating a new and topical agenda, year on year.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement